Abstract
Get full access to this article
View all access options for this article.
References
1.
Bluebird Bio. Form 10-K annual report for 2021. Filed March 4, 2022, with the U.S. Securities and Exchange Commission. https://investor.bluebirdbio.com/static-files/b5cf7b5a-ff26-4ebc-8d9e-9c99d9701b7a (last accessed
March 12 , 2022
).
2.Code Biotherapeutics. Code Biotherapeutics announces collaboration with Takeda to use proprietary 3DNA genetic medicine delivery platform to design and develop gene therapies for rare diseases. 2022 . https://www.codebiotx.com/news-february-22-2022 (last accessed
March 12 , 2022
).
3.Voyager Therapeutics . Voyager Therapeutics announces license option agreement with Novartis for target-specific access to next-generation TRACER™ AAV capsids for gene therapy programs. 2022. https://ir.voyagertherapeutics.com/news-releases/news-release-details/voyager-therapeutics-announces-license-option-agreement-novartis (last accessed
March 12 , 2022
).
4.Amicus Therapeutics . Amicus Therapeutics announces full-year 2021 financial results and corporate updates. 2022. https://ir.amicusrx.com/news-releases/news-release-details/amicus-therapeutics-announces-full-year-2021-financial-results (last accessed
March 12 , 2022
).
5.Seeking Alpha . Amicus Therapeutics' (FOLD) CEO John Crowley on Q4 2021 Results - earnings call transcript. 2022. https://seekingalpha.com/article/4490157-amicus-therapeutics-fold-ceo-john-crowley-on-q4-2021-results-earnings-call-transcript (last accessed
March 13 , 2022
).
6.UCB . UCB expands innovation footprint with new state-of-the-art gene therapy facility. 2022. https://www.ucb.com/stories-media/Press-Releases/article/UCB-expands-innovation-footprint-with-new-state-of-the-art-gene-therapy-facility (last accessed
March 12 , 2022
).
7.
Philippidis
A
. Third phase: synthego expanding cell, gene therapy capabilities with $200M financing. Genetic Engineering & Biotechnology News (GEN Edge). 2022. https://www.genengnews.com/topics/genome-editing/third-phase-synthego-expanding-cell-gene-therapy-capabilities-with-200m-financing/ (last accessed
March 13 , 2022
).
8.Selecta Biosciences . Selecta biosciences reports fourth quarter and full year 2021 financial results and provides business update. 2022. https://ir.selectabio.com/news-releases/news-release-details/selecta-biosciences-reports-fourth-quarter-and-full-year-2021 (last accessed
March 12 , 2022
).